# A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

> **NCT02149524** · PHASE3 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 875 (actual)

## Conditions studied

- HER2 Positive Early or Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Herceptin (trastuzuamb)
- **DRUG:** SB3 (proposed trastuzumab biosimilar)

## Key facts

- **NCT ID:** NCT02149524
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-03
- **Final completion:** 2017-02
- **Target enrollment:** 875 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149524, "A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02149524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*